Biotech

ABBVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021 .

"We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations," said Richard A. Gonzalez , chairman and chief executive officer, AbbVie. "Our new products are delivering impressive performance and we are on the cusp of potential commercial approvals for more than a dozen new products or indications over the next two years – including five expected approvals in 2021."

First-Quarter Results

  • Worldwide GAAP net revenues were $13.010 billion , an increase of 51.0 percent on a reported basis. Worldwide adjusted net revenues of $12.935 billion increased 5.2 percent on a comparable operational basis.
  • Global net revenues from the immunology portfolio were $5.744 billion , an increase of 12.9 percent on a reported basis, or 11.8 percent on an operational basis.
    • Global Humira net revenues of $4.867 billion increased 3.5 percent on a reported basis, or 2.6 percent on an operational basis. U.S. Humira net revenues were $3.907 billion , an increase of 6.9 percent. Internationally, Humira net revenues were $960 million , a decrease of 8.3 percent on a reported basis, or 12.6 percent on an operational basis, due to biosimilar competition.
    • Global Skyrizi net revenues were $574 million .
    • Global Rinvoq net revenues were $303 million .
  • Global net revenues from the hematologic oncology portfolio were $1.673 billion , an increase of 8.0 percent on a reported basis, or 7.3 percent on an operational basis.
    • Global Imbruvica net revenues were $1.268 billion , an increase of 2.9 percent, with U.S. net revenues of $999 million and international profit sharing of $269 million .
    • Global Venclexta net revenues were $405 million , an increase of 27.9 percent on a reported basis, or 24.5 percent on an operational basis.
  • Global net revenues from the aesthetics portfolio were $1.141 billion , an increase of 34.9 percent on a comparable operational basis.
    • Global Botox Cosmetic net revenues were $477 million , an increase of 44.7 percent on a comparable operational basis.
  • Global net revenues from the neuroscience portfolio were $1.248 billion , an increase of over 100.0 percent on a reported basis, or 10.9 percent on a comparable operational basis.
    • Global Botox Therapeutic net revenues were $532 million , an increase of 7.0 percent on a comparable operational basis.
    • Global Vraylar net revenues were $346 million , an increase of 21.2 percent on a comparable operational basis.
    • Global Ubrelvy net revenues were $81 million .
  • On a GAAP basis, the gross margin ratio in the first quarter was 67.6 percent. The adjusted gross margin ratio was 83.9 percent.
  • On a GAAP basis, selling, general and administrative expense was 21.8 percent of net revenues. The adjusted SG&A expense was 21.2 percent of net revenues.
  • On a GAAP basis, research and development expense was 13.7 percent of net revenues. The adjusted R&D expense was 11.6 percent of net revenues, reflecting funding actions supporting all stages of our pipeline.
  • On a GAAP basis, the operating margin in the first quarter was 31.5 percent. The adjusted operating margin was 51.0 percent.
  • On a GAAP basis, net interest expense was $622 million .
  • On a GAAP basis, the tax rate in the quarter was 8.1 percent. The adjusted tax rate was 12.3 percent.
  • Diluted EPS in the first quarter was $1.99 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $2.95 .

Note: "Comparable Operational" comparisons include full-quarter current year and prior year results for Allergan, which was acquired on May 8, 2020 , as if the acquisition closed on January 1, 2019 , and are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates. Refer to the Key Product Revenues schedules for further details. "Operational" comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates.

Recent Events

  • AbbVie announced that it submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab, 150 mg) for the treatment of adults with active psoriatic arthritis (PsA). The applications are supported by two Phase 3 studies in which Skyrizi demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo. The safety profile of Skyrizi in these studies was generally consistent with the safety profile of Skyrizi in plaque psoriasis, with no new safety risks observed. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
  • AbbVie announced positive results from the Phase 3 induction study, U-ACCOMPLISH, which showed Rinvoq (upadacitinib, 45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8 in adult patients with moderate to severe ulcerative colitis (UC). Additionally, all ranked secondary endpoints, including clinical, endoscopic and histologic outcomes, were met. U-ACCOMPLISH is the second of two Phase 3 induction studies to evaluate the safety and efficacy of Rinvoq in adults with moderate to severe UC and the results were consistent with findings from the first Phase 3 induction study, U-ACHIEVE. Safety results were also consistent with the previous Phase 3 induction study and the known profile of Rinvoq, with no new safety risks observed. Full results from the study will be presented at a future medical meeting and submitted for publication in a peer-reviewed journal. Results from the Phase 3 maintenance study and regulatory submissions are expected in 2H 2021.
  • AbbVie announced that the FDA extended the review period for the supplemental New Drug Applications (sNDA) for Rinvoq in the treatment of adult patients with active PsA as well as in the treatment of adults and adolescents with moderate to severe atopic dermatitis (AD). AbbVie received information requests from the FDA for an updated assessment of the benefit-risk profile for Rinvoq in both indications. AbbVie responded to the requests and the FDA will require additional time for a full review of the submissions. The updated Prescription Drug User Fee Act (PDUFA) action dates have been extended three months to late 2Q 2021 for PsA and early 3Q 2021 for AD.
  • AbbVie announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion for Venclyxto (venetoclax) in combination with hypomethylating agents for the treatment of adult patients with newly-diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. The positive CHMP opinion is based on data from the VIALE-A and M14-358 trials and represents the third positive CHMP opinion for an extension of indications for Venclyxto. If approved by the European Commission (EC), Venclyxto in combination with hypomethylating agents would be a new regimen for patients with AML. The EC is expected to deliver its final decision on Venclyxto combination therapy for use in AML in 2Q 2021. Venetoclax is being developed by AbbVie and Roche and is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.
  • AbbVie announced the FDA accepted its New Drug Application (NDA) for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), for the preventive treatment of migraine in adults who meet criteria for episodic migraine. The NDA is supported by data from a clinical program evaluating the efficacy, safety and tolerability of orally administered atogepant in nearly 2,500 patients who experience 4-14 migraine days per month, including data from the pivotal Phase 3 ADVANCE study in which all active treatment arms of atogepant met their primary endpoint and the 30 and 60 mg doses met all six secondary endpoints with statistical significance. If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine. AbbVie anticipates a regulatory decision in late 3Q 2021.
  • At the 2021 American Academy of Neurology (AAN) Annual Meeting, ABBVie presented data across its neuroscience portfolio. A total of 33 abstracts, including 4 oral presentations, were shared from a broad range of studies across the spectrum of migraine, advanced Parkinson's disease (PD) and spasticity. Researchers presented migraine related data from the Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine, real-world data on the role of Botox (onabotulinumtoxinA) in combination with CGRP monoclonal antibodies (mAbs) for chronic migraine prevention, as well as data evaluating the efficacy and safety of Botox and Ubrelvy (ubrogepant). In addition, investigators presented the study design of the Phase 3 study assessing the efficacy and safety of the investigational treatment ABBV-951 (foslevodopa/foscarbidopa), a levodopa/carbidopa prodrug administered as a 24-hour continuous subcutaneous infusion, in people with advanced PD.
  • AbbVie announced that it submitted a NDA to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly half of the adult U.S. population. The application is primarily based on data from two pivotal Phase 3 studies involving 750 patients. In both studies AGN-190584 met the primary endpoint reaching statistical significance in improvement in near vision without a loss of distance vision. If approved, AGN-190584 is expected to be the first eye drop to treat presbyopia and the FDA is expected to act on the NDA by the end of 2021.
  • AbbVie announced the launch of Refresh Digital lubricant eye drops, a new lubricant eye drop formulated to specifically relieve dryness and irritation that may occur from prolonged screen time. Refresh Digital features proprietary HydroCell technology that supports all three layers of the tear film to keep eyes hydrated.
  • Allergan Aesthetics announced the launch of SkinMedica Neck Correct Cream, the first product from the professional-grade skincare line formulated to address the specific biology of the skin on the neck and décolleté area. SkinMedica Neck Correct Cream was designed to prevent the early signs as well as treat the visible appearance of moderate to severe neck aging. It is clinically proven to firm and tighten the look of crepey skin, prevent and reduce the look of sagging, smooth deep lines and wrinkles and enhance skin tone evenness.
  • AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Under the multi-year agreement, AbbVie will utilize Caribou's next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie.

Full-Year 2021 Outlook

AbbVie is raising its GAAP diluted EPS guidance for the full-year 2021 from $6.69 to $6.89 to $7.27 to $7.47 . AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.32 to $12.52 to $12.37 to $12.57 . The company's 2021 adjusted diluted EPS guidance excludes $5.10 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter, Facebook or LinkedIn .

Conference Call

AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our first-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the call will be available after 11:00 a.m. Central time .

Non-GAAP Financial Results

Financial results for 2021 and 2020 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company's 2021 financial guidance is also being provided on both a reported and a non-GAAP basis.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie's acquisition of Allergan or to promptly and effectively integrate Allergan's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

AbbVie Inc.

Key Product Revenues

Quarter Ended March 31, 2021

(Unaudited)









% Change vs. 1Q20


Net Revenues (in millions)


Reported


Comparable Operational a, b


U.S.


Int'l.


Total


U.S.


Int'l.


Total


U.S.


Int'l


Total

ADJUSTED NET REVENUES c

$9,675


$3,260


$12,935


57.1%


32.5%


50.1%


7.3%


(0.7)%


5.2%



















Immunology

4,633


1,111


5,744


15.7


2.3


12.9


15.7


(2.8)


11.8

Humira

3,907


960


4,867


6.9


(8.3)


3.5


6.9


(12.6)


2.6

Skyrizi

481


93


574


80.6


>100.0


91.1


80.6


>100.0


88.9

Rinvoq

245


58


303


>100.0


>100.0


>100.0


>100.0


>100.0


>100.0



















Hematologic Oncology

1,224


449


1,673


4.8


17.7


8.0


4.8


14.9


7.3

Imbruvica d

999


269


1,268


3.3


1.4


2.9


3.3


1.4


2.9

Venclexta

225


180


405


12.2


54.9


27.9


12.2


45.6


24.5



















Aesthetics

728


413


1,141


n/m


n/m


n/m


23.8


61.2


34.9

Botox Cosmetic*

305


172


477


n/m


n/m


n/m


43.1


47.7


44.7

Juvederm Collection*

123


198


321


n/m


n/m


n/m


14.9


69.6


43.0

Other Aesthetics*

300


43


343


n/m


n/m


n/m


12.1


87.4


17.8



















Neuroscience

1,037


211


1,248


>100.0


>100.0


>100.0


12.9


1.5


10.9

Botox Therapeutic*

429


103


532


n/m


n/m


n/m


6.7


8.0


7.0

Vraylar*

346



346


n/m


n/a


n/m


21.2


n/a


21.2

Duodopa

25


104


129


0.8


4.7


3.9


0.8


(4.5)


(3.4)

Ubrelvy*

81



81


n/m


n/a


n/m


>100.0


n/a


>100.0

Other Neuroscience*

156


4


160


n/m


n/m


n/m


(19.5)


2.0


(19.1)



















Eye Care

530


287


817


n/m


n/m


n/m


(12.7)


(1.8)


(9.2)

Lumigan/Ganfort*

66


77


143


n/m


n/m


n/m


(18.4)


(9.7)


(14.1)

Alphagan/Combigan*

80


38


118


n/m


n/m


n/m


(13.5)


4.1


(8.5)

Restasis*

267


13


280


n/m


n/m


n/m


(14.9)


19.3


(13.8)

Other Eye Care*

117


159


276


n/m


n/m


n/m


(2.4)


(0.4)


(1.3)



















Women's Health

177


3


180


>100.0


>100.0


>100.0


(19.6)


(61.0)


(21.2)

Lo Loestrin*

102


2


104


n/m


n/m


n/m


(11.2)


(8.1)


(11.1)

Orilissa/Oriahnn

29


1


30


(5.0)


58.8


(3.3)


(5.0)


52.8


(3.5)

Other Women's Health*

46



46


n/m


n/m


n/m


(38.1)


(100.0)


(42.8)



















Other Key Products

1,021


294


1,315


12.4


(19.1)


3.4


(7.3)


(25.1)


(11.7)

Mavyret

170


245


415


(26.9)


(24.8)


(25.7)


(26.9)


(29.5)


(28.4)

Creon

274



274


(0.9)


n/a


(0.9)


(0.9)


n/a


(0.9)

Lupron

171


42


213


(12.1)


10.8


(8.3)


(12.1)


9.0


(8.6)

Linzess/Constella*

215


7


222


n/m


n/m


n/m


11.7


(6.6)


11.1

Synthroid

191



191


(6.8)


n/a


(6.8)


(6.8)


n/a


(6.8)


a "Comparable Operational" comparisons include full-quarter current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

b All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items.

c Adjusted net revenues exclude specified items. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Percentage change is calculated using adjusted net revenues.

d Reflects profit sharing for Imbruvica international revenues.

* Represents product(s) acquired as part of the Allergan acquisition.

n/a = not applicable

n/m = not meaningful

AbbVie Inc.

Consolidated Statements of Earnings

Quarter Ended March 31, 2021 and 2020

(Unaudited) (In millions, except per share data)




First Quarter
Ended March 31



2021


2020

Net revenues


$

13,010



$

8,619


Cost of products sold


4,213



1,942


Selling, general and administrative


2,842



1,695


Research and development


1,782



1,379


Acquired in-process research and development


70




Total operating costs and expenses


8,907



5,016







Operating earnings


4,103



3,603







Interest expense, net


622



428


Net foreign exchange loss


9



5


Other expense (income), net


(395)



72


Earnings before income tax expense


3,867



3,098


Income tax expense


312



88


Net earnings


3,555



3,010


Net earnings attributable to noncontrolling interest


2




Net earnings attributable to AbbVie Inc.


$

3,553



$

3,010







Diluted earnings per share attributable to AbbVie Inc.


$

1.99



$

2.02







Adjusted diluted earnings per share a


$

2.95



$

2.42







Weighted-average diluted shares outstanding


1,775



1,484



a Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

Quarter Ended March 31, 2021

(Unaudited) (In millions, except per share data)


1.     Specified items impacted results as follows:




1Q21



Earnings


Diluted



Pre-tax


After-tax a


EPS

As reported (GAAP)

$

3,867



$

3,553



$

1.99


Adjusted for specified items:






Intangible asset amortization

2,009



1,682



0.94


Milestones and other R&D expenses

210



180



0.10


Acquisition and integration costs

224



155



0.09


Acquired IPR&D

70



62



0.03


Change in fair value of contingent consideration

(343)



(343)



(0.19)


Other

(29)



(21)



(0.01)


As adjusted (non-GAAP)

$

6,008



$

5,268



$

2.95



a Represents net earnings attributable to AbbVie Inc.


Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Acquisition and integration costs reflect integration costs as well as amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Other primarily includes milestone revenue under an existing collaboration agreement, restructuring charges associated with streamlining global operations and COVID-19 related expenses.


2.     The impact of the specified items by line item was as follows:




1Q21


Net
revenues


Cost of
products
sold


SG&A


R&D


Acquired
IPR&D


Other
expense
(income),
net

As reported (GAAP)

$

13,010



$

4,213



$

2,842



$

1,782



$

70



$

(395)


Adjusted for specified items:












Intangible asset amortization



(2,009)










Milestones and other R&D expenses







(210)






Acquisition and integration costs



(99)



(76)



(49)






Acquired IPR&D









(70)




Change in fair value of contingent consideration











343


Other

(75)



(20)



(23)



(18)





15


As adjusted (non-GAAP)

$

12,935



$

2,085



$

2,743



$

1,505



$



$

(37)



3.     The adjusted tax rate for the first quarter of 2021 was 12.3 percent, as detailed below:




1Q21



Pre-tax
earnings


Income
taxes


Tax rate

As reported (GAAP)


$

3,867



$

312




8.1

%

Specified items


2,141



426




19.9

%

As adjusted (non-GAAP)


$

6,008



$

738




12.3

%




AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

Quarter Ended March 31, 2020

(Unaudited) (In millions, except per share data)


1.     Specified items impacted results as follows:



1Q20


Earnings


Diluted


Pre-tax


After-tax a


EPS

As reported (GAAP)

$

3,098



$

3,010



$

2.02


Adjusted for specified items:






Intangible asset amortization

444



371



0.24


Acquisition related costs

188



158



0.11


Milestones and other R&D expenses

135



115



0.08


Change in fair value of contingent consideration

72



72



0.05


Other

66



(113)



(0.08)


As adjusted (non-GAAP)

$

4,003



$

3,613



$

2.42



a Represents net earnings attributable to AbbVie Inc.


Acquisition related costs reflect transaction and financing costs related to the Allergan acquisition. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Other primarily includes the impacts of tax law changes, charitable contributions to support COVID-19 relief efforts and restructuring charges associated with streamlining global operations.


2.     The impact of the specified items by line item was as follows:



1Q20


Cost of
products
sold


SG&A


R&D


Interest
expense,
net


Other
expense
(income),
net

As reported (GAAP)

$

1,942



$

1,695



$

1,379



$

428



$

72


Adjusted for specified items:










Intangible asset amortization

(444)










Acquisition related costs



(44)





(144)




Milestones and other R&D expenses





(135)






Change in fair value of contingent consideration









(72)


Other

(4)



(52)



(10)






As adjusted (non-GAAP)

$

1,494



$

1,599



$

1,234



$

284



$



3.     The adjusted tax rate for the first quarter of 2020 was 9.7 percent, as detailed below:




1Q20



Pre-tax

earnings


Income

taxes


Tax rate

As reported (GAAP)


$

3,098



$

88




2.8

%

Specified items


905



302




33.4

%

As adjusted (non-GAAP)


$

4,003



$

390




9.7

%


Cision View original content: http://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2021-financial-results-301281124.html

SOURCE AbbVie

News Provided by PR Newswire via QuoteMedia

LAWSUITS FILED AGAINST AUPH, ARQQ and AMZN - Jakubowitz Law Pursues Shareholders Claims

Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABBV, SDIG and NTRA

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

ABBVie Inc. (NYSE:ABBV)
Class Period: April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline: June 6, 2022

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has activated Hoag Memorial Hospital Presbyterian ("Hoag") and re-engaged Sylvester Comprehensive Cancer Center, part of UHealth the University of Miami Health System, as two additional clinical sites for the screening and enrollment of advanced breast cancer patients in the Phase IIIa combination study of BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat.

"While we continue to steadily accrue patients in our ongoing clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors, the addition of these clinical sites should help further accelerate patient enrollment in the clinical trial. We look forward to discussing our safety and efficacy data with the FDA, now with Fast Track status , to plan our pivotal registration study and remain on track to achieve this major milestone in 2022," stated Dr. Bill Williams, BriaCell's President & CEO.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Naturally Splendid Update for Management Cease Trade Order

Naturally Splendid Update for Management Cease Trade Order

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N) (TSX-V:NSP) (OTC:NSPDF) announces an update regarding the application to the British Columbia and Alberta Securities Commission to approve temporary management cease trade order ("MCTO") under National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"), which, if granted, will prohibit trading securities by the Company by the Chief Executive Officer and Chief Financial Officer of the Corporation until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted. During the period in which the MCTO is effective, the general public, who are not insiders of the Company, will continue to be able to trade in the Company's listed securities

The Company has received approval from the British Columbia and Alberta Securities Commission and the Company anticipates that it will be in a position to remedy the default by filing the Required Filings on or about June 30, 2022. The MCTO will be in effect until the Required Filings are filed.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of IBM, MYPS and AUPH

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

International Business Machines Corporation (NYSE:IBM)
Class Period: April 4, 2017 - October 20, 2021
Lead Plaintiff Deadline: June 6, 2022

Throughout the class period, International Business Machines Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue and growth, CAMSS and CAMSS Components' revenue and growth, and the Company's Segments' revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (ii) the Company's present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue and, as a result (iii) the Company misled the market by portraying the Company's Strategic Imperative's financial performance and future prospects more favorable than they actually were as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less
The Gummy Project

Potent Ventures Announces The Gummy Project Selected by Sweets & Snack Expo Committee to Participate in Power Pitch During Sweets & Snacks Expo

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is pleased to announce that The Gummy Project is one of two companies selected from the show's Startup Street to participate in Power Pitch at Sweets & Snacks Expo on May 24, 2022.

Power Pitch provides selected companies with an opportunity to showcase their products in a sales pitch-style presentation to a panel of leading US retailers, including the following:

Keep reading...Show less

Latest Press Releases

Related News

×